- AMRI (AMRI +3.9%) acquires Oso Biopharmaceuticals Manufacturing LLC (OsoBio) for $110M cash. OsoBio is a contract manufacturer of injectable drug products, including sterile liquid, suspension and lyophilized formulations. President & CEO William S. Marth says, "The acquisition of OsoBio is highly complementary to our finished dose manufacturing business and is consistent with our strategy to be the preeminent supplier of custom and complex drug development services and products to the pharmaceutical industry."
- On a stand-alone basis, OsoBio's 2014 revenue is expected to be $58M - 60M and EBITDA between $9M - 10M.
at MarketWatch.com (Oct 14, 2014)